Boundless Bio, Inc.
BOLD · XNASCIK 1782303fmd_17NBPVCBYK7WYH312FXE78PTAZManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2023 to Sep 30, 2026, 15 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Research and development | 43 | 55 | 45 |
| Total operating expenses | 55 | 73 | 64 |
| Operating income | (55) | (73) | (64) |
| Interest and investment income | 5 | 8 | 5 |
| Other non-operating income (expense) | 5 | 8 | 5 |
| Income tax expense | – | 0 | 0 |
| Net income | (49) | (65) | (58) |